Video Upload Options

References

1. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, Saltness RA,Jeganathan KB, Verzosa GC, Pezeshki A, Khazaie K, Miller JD, van Deursen JM.Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature.2016 Feb 11;530(7589):184-9. doi: 10.1038/nature16932.
2. Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, OgaraMF. INK4 proteins, a family of mammalian CDK inhibitors with novel biologicalfunctions. IUBMB Life. 2007 Jul;59(7):419-26. Review.
3. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E,Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D,Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM,Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S,Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genesand pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.Cancer Res. 2006 Oct 15;66(20):9818-28.
4. He S, Sharpless NE. Senescence in Health and Disease. Cell. 2017 Jun1;169(6):1000-1011. doi: 10.1016/j.cell.2017.05.015. Review.
5. Jeck WR, Siebold AP, Sharpless NE. Review: a meta-analysis of GWAS andage-associated diseases. Aging Cell. 2012 Oct;11(5):727-31. doi:10.1111/j.1474-9726.2012.00871.x.
6. Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J,Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, SolomonB. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamouscell carcinomas and correlation with patient outcome. Int J Cancer. 2014 Aug15;135(4):887-95. doi: 10.1002/ijc.28727.
7. Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N. Lessons learned from next-generation sequencing in head and neck cancer. HeadNeck. 2013 Mar;35(3):454-63. doi: 10.1002/hed.23100.
8. Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cellcarcinoma of the head and neck: targetable genetic events and clinical impact.Ann Oncol. 2014 Oct;25(10):1889-1900. doi: 10.1093/annonc/mdu143.
9. Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, Puig S. Increased prevalence of lung, breast, and pancreatic cancers in addition tomelanoma risk in families bearing the cyclin-dependent kinase inhibitor 2Amutation: implications for genetic counseling. J Am Acad Dermatol. 2014Nov;71(5):888-95. doi: 10.1016/j.jaad.2014.06.036.
10. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, KryukovGV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, CarterSL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC,Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C,Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K,Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. Themutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130.
11. Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W,Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA,Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC,Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Ingvar C, Landi MT, LandmanG, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR,Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of MelanomaFamilies. J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi:10.1016/j.jid.2017.07.829.